Without it, your risk of gum disease and cavities increases.Chronic mouth breathing in children may affect dental and facial growth. It may also lead to the development of a long, narrow face, sometimes termed long face syndrome. Conversely, it has been suggested that a long thin face type, with corresponding thin nasopharyngeal airway, predisposes to nasal obstruction and mouth breathing. Additional approaches to mouth breathing
George Catlin
George Catlin was a 19th-century American painter, author, and traveler, who specialized in portraits of Native Americans in the Old West. Travelling to the American West five times during the 1830s, he wrote about, and painted portraits that depicted, the life of the Plains Indians. He was also the author of several books, including The Breath of Life (later retitled as Shut Your Mouth and Save Your Life) in 1862. It was based on his experiences traveling through the West, where he observed a consistent lifestyle habit among the Native American communities he encountered: a preference for nose breathing over mouth breathing. He also observed that they had perfectly straight teeth. He repeatedly heard that this was because they believed that mouth breathing made an individual weak and caused disease, while nasal breathing made the body strong and prevented disease. He also observed that mothers repeatedly closed the mouth of their infants while they were sleeping, to instill nasal breathing as a habit.
The applicant for this medicinal product is Merck Europe B.V. Tepotinib (Tepmetko) was approved for medical use in the European Union in February 2022. References
Further reading
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC,  et al. (September 2020). "Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations". N Engl J Med. 383 (10): 931–43. doi:10.1056/NEJMoa2004407. PMC 8422679. PMID 32469185. External links
"Tepotinib". Drug Information Portal. U.S. National Library of Medicine. "Tepotinib hydrochloride". Drug Information Portal. U.S. National Library of Medicine. "Tepotinib hydrochloride". NCI Drug Dictionary. National Cancer Institute. Clinical trial number NCT02864992 for "Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations (VISION)" at ClinicalTrials.gov